Premium-Grade Research Peptides You Can Trust!!
DSIP (Delta Sleep-Inducing Peptide) is primarily associated with sleep regulation and its ability to modulate sleep patterns. It has been linked to promoting delta-wave sleep, which is the deep, restorative stage of non-REM sleep.
DSIP influences the hypothalamic-pituitary-adrenal (HPA) axis, helping to maintain hormonal balance (such as cortisol) and reduce stress-related disruptions.
DSIP has also been shown to support neuronal health and cellular repair, as well as modulate metabolic activity within the central nervous system. It has been shown to improve sleep quality, reduce stress-related symptoms, and support overall recovery processes.
As a result, users will experience more restorative, consistent sleep.
Enhanced purity standards with third-party verification and GMP certification.
Recommended Dose: Inject 5 units (500mcg) daily.
Administration: Subcutaneous injection
Timing: On an empty stomach, at least 1 hour before/after eating..
Cycle: Best results occur when taken consistently for 4-12 weeks.
99% Purity tested via HPLC methods.
Store in a cool and dry place away from children.
3 vials, all supplies included
9 vials, all supplies included
Using our dosage recommendations listed above, 1 vial will provide 40 500mcg (5 unit) doses, lasting 5.71 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vial can be used, if desired. However, only 28 doses are needed for the 4 week protocol.
Using our dosage recommendations listed above, 3 vials will provide 120 500mcg (5 unit) doses, lasting 17.14 weeks.Due to the overage of peptide solution in the vial, we provide extra syringes and wipes to ensure the entirety of the vials can be used, if desired. However, only 84 doses are needed for the 12 week protocol.
In a p-chlorophenylalanine-induced insomnia mouse model, DSIP demonstrated significant sleep-promoting effects, restored neurotransmitter balance (e.g., increased dopamine), improved neuron density, and neuroprotective benefits comparable to or better than GABA, highlighting potential for advanced sleep therapies.
Read StudyPublished in 2021 in Molecules, this preclinical study showed that DSIP administration (120 µg/kg for 8 days) before and after middle cerebral artery occlusion in rats accelerated motor function recovery (e.g., improved coordination and reduced asymmetry in behavioral tests), suggesting neuroprotective mechanisms via antioxidant activity and modulation of glutamate/GABA systems post-ischemia.
Read StudyPublished in 2017, this study engineered a DSIP fusion protein (with TAT transduction domain and human serum albumin) for better stability and delivery. In pentobarbital-induced sleep tests in mice, subcutaneous injections (0.5–2 mg/kg) reduced sleep latency and prolonged duration, supporting enhanced hypnotic effects and potential as a candidate for insomnia treatment.
Read Study



Based on 0 reviews
You must be logged in to post a review.
There are no reviews yet.
Reviews